Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200628582> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4200628582 abstract "To evaluate in clinical practice the persistence and safety of golimumab, together with the evolution of disease activity and patient reported outcomes, in adult patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (axSpA). This article focuses on the outcomes of golimumab treatment in axSpA patients.Golimumab persistence 24 months after initial prescription (primary outcome) was assessed using Kaplan-Meier estimates. Secondary outcomes included evaluations of disease activity evolution (ASDAS and BASDAI), patient-reported outcomes (EQ-5D, SF-12 and HAQ), and golimumab's safety profile.Of 478 axSpA patients, 60.9% were biologic-naïve. Mean age and proportion of females were higher in biologics-pretreated patients (46.8 vs. 40.2 years, p<0.001 and 62.0% vs. 49.8%, p=0.009, respectively). Golimumab persistence at 24 months was 52.6% [95% CI 47.9-57.1%] in the axSpA cohort. It was 59.2% [95% CI 53.1-64.8%] and 42.7% [95% CI 35.3-49.8%] respectively, for biologics-naïve and biologics-pretreated patients (p<0.01), and 65.9% [95% CI 58.9-72.0%] and 41.5% [95% CI 35.2-47.6%], respectively for males and females (p<0.01). Reasons for golimumab discontinuation were primary non-response (37.4%), secondary non-response (24.8%) and intolerance (21.5%). Disease activity and patient reported outcomes improved significantly for those who persisted at 24 months and were higher for biologics-naïve patients.Golimumab persistence at 2 years in axSpA patients was 52.6%. Previous treatment with another biologic and female gender were associated with earlier discontinuation. Golimumab was a well-tolerated therapy for axSpA, with no new safety signals observed." @default.
- W4200628582 created "2021-12-31" @default.
- W4200628582 creator A5009864916 @default.
- W4200628582 creator A5010199500 @default.
- W4200628582 creator A5015032522 @default.
- W4200628582 creator A5023087552 @default.
- W4200628582 creator A5031211618 @default.
- W4200628582 creator A5035104777 @default.
- W4200628582 creator A5043661644 @default.
- W4200628582 creator A5052636813 @default.
- W4200628582 creator A5086242828 @default.
- W4200628582 date "2021-03-24" @default.
- W4200628582 modified "2023-10-08" @default.
- W4200628582 title "Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE" @default.
- W4200628582 doi "https://doi.org/10.55563/clinexprheumatol/ua3uqe" @default.
- W4200628582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34936548" @default.
- W4200628582 hasPublicationYear "2021" @default.
- W4200628582 type Work @default.
- W4200628582 citedByCount "2" @default.
- W4200628582 countsByYear W42006285822022 @default.
- W4200628582 crossrefType "journal-article" @default.
- W4200628582 hasAuthorship W4200628582A5009864916 @default.
- W4200628582 hasAuthorship W4200628582A5010199500 @default.
- W4200628582 hasAuthorship W4200628582A5015032522 @default.
- W4200628582 hasAuthorship W4200628582A5023087552 @default.
- W4200628582 hasAuthorship W4200628582A5031211618 @default.
- W4200628582 hasAuthorship W4200628582A5035104777 @default.
- W4200628582 hasAuthorship W4200628582A5043661644 @default.
- W4200628582 hasAuthorship W4200628582A5052636813 @default.
- W4200628582 hasAuthorship W4200628582A5086242828 @default.
- W4200628582 hasConcept C126322002 @default.
- W4200628582 hasConcept C1862650 @default.
- W4200628582 hasConcept C2776260265 @default.
- W4200628582 hasConcept C2777226972 @default.
- W4200628582 hasConcept C2777453003 @default.
- W4200628582 hasConcept C2777575956 @default.
- W4200628582 hasConcept C2778715236 @default.
- W4200628582 hasConcept C2781290027 @default.
- W4200628582 hasConcept C71924100 @default.
- W4200628582 hasConcept C72563966 @default.
- W4200628582 hasConceptScore W4200628582C126322002 @default.
- W4200628582 hasConceptScore W4200628582C1862650 @default.
- W4200628582 hasConceptScore W4200628582C2776260265 @default.
- W4200628582 hasConceptScore W4200628582C2777226972 @default.
- W4200628582 hasConceptScore W4200628582C2777453003 @default.
- W4200628582 hasConceptScore W4200628582C2777575956 @default.
- W4200628582 hasConceptScore W4200628582C2778715236 @default.
- W4200628582 hasConceptScore W4200628582C2781290027 @default.
- W4200628582 hasConceptScore W4200628582C71924100 @default.
- W4200628582 hasConceptScore W4200628582C72563966 @default.
- W4200628582 hasLocation W42006285821 @default.
- W4200628582 hasLocation W42006285822 @default.
- W4200628582 hasLocation W42006285823 @default.
- W4200628582 hasOpenAccess W4200628582 @default.
- W4200628582 hasPrimaryLocation W42006285821 @default.
- W4200628582 hasRelatedWork W1962656519 @default.
- W4200628582 hasRelatedWork W1977429519 @default.
- W4200628582 hasRelatedWork W2071607310 @default.
- W4200628582 hasRelatedWork W2072412214 @default.
- W4200628582 hasRelatedWork W2169072445 @default.
- W4200628582 hasRelatedWork W2317739744 @default.
- W4200628582 hasRelatedWork W2611448469 @default.
- W4200628582 hasRelatedWork W2985978333 @default.
- W4200628582 hasRelatedWork W3176633767 @default.
- W4200628582 hasRelatedWork W4235629817 @default.
- W4200628582 isParatext "false" @default.
- W4200628582 isRetracted "false" @default.
- W4200628582 workType "article" @default.